Respiratory Syncytial Virus – Epidemiology Forecast to 2030

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

The Respiratory Syncytial Virus (RSV) prophylactic population in the eight major markets (*8MM) is projected to increase from over 14.55 million cases in 2020 to 15.64 million in 2030, with an annual growth rate (AGR) of 0.75%. This report estimates that in 2030, the US will have the highest number of prophylactic eligible individuals across the 8MM, with over 6.53 million individuals. Spain will have the lowest number of prophylactic eligible individuals with approximately 0.66 million individuals.

In the *5EU, GlobalData estimates that in 2030 there to be over 6.32 million prophylactic eligible individuals, while Japan and Australia will have over 2.04 million and over 0.74 million prophylactic eligible individuals, respectively.

PR13890.png

Walter Gabriel, MPH, Epidemiologist at GlobalData, comments: “The primary driver of change in the prophylactic population is the underlying demographics, specifically in the pediatric and elderly populations.”

While RSV currently does not have a known cure nor a vaccine, preventive measures can be taken to help mitigate the spread of infection. As such, understanding the prevalence of individuals who are at greatest risk of severe complications from RSV is critical to curbing exposure of the virus and administering prophylactic therapy to reduce the likelihood of severe RSV infection.

Gabriel concludes: “Although GlobalData epidemiologists do not expect any significant changes that would reduce the size of the prophylactic population, changes may always occur in the future with the development of new treatments for at-risk populations.”

*8MM: The US, France, Germany, Italy, Spain, the UK, Japan, and Australia

Scope

Respiratory syncytial virus (RSV) is a common respiratory infection that most children will be infected with by the time they are two years old. In healthy individuals, RSV usually self-resolves within a week or two without need for significant therapeutic intervention. In preterm and very young infants, the elderly, or those with otherwise compromised immune systems, however, RSV can cause severe illness or death.

GlobalData epidemiologists provide a well-rounded, evidence-based analysis and forecast for the prophylactic populations for RSV in this report. This analysis covered all at-risk groups that are recommended for RSV prophylactic treatment. Several of the segmentations are further segmented by age, thereby providing a granular visualization of the RSV prophylactic and hospitalized market in the 8MM.

This report provides an overview of the risk factors, and global and historical trends for the RSV prophylactic population in the 8MM. It also includes a 10-year epidemiology forecast for the pediatric and adult populations that are most at risk for severe RSV infection and are therefore eligible to receive prophylactic treatment (prophylactic population). The Excel model accompanying the report also contains the RSV seroprevalent population.

  • The Respiratory Syncytial Virus (RSV) Epidemiology Report and Model provide an overview of the global trends in risk factors for RSV in the seven major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and Australia).
  • The report includes a 10-year epidemiological forecast for the pediatric and adult populations that are at most risk for severe RSV infection and are therefore eligible for prophylactic treatment. This prophylactic population consists of: children born before 37 weeks of gestation (preterm population); preterm births with neonatal chronic lung disease (CLD); live births with hemodynamically significant congenital heart disease; boys 0-2 years old with
  • Duchenne muscular dystrophy (DMD); children 0-2 years old with spinal muscular atrophy (SMA); pregnant women in their third trimester; and adults ≥ 55 years of age living in nursing homes or other long-term care institutions. The Excel model accompanying the report also contains the RSV seroprevalent population.
  • The RSV epidemiology report and model were written and developed by Masters- and PhD-level epidemiologists.
  • The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.
  • The Epidemiology Model is easy to navigate, interactive with dashboards, and epidemiology-based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources.

Reasons to Buy

The RSV Epidemiology series will allow you to:

  • Develop business strategies by understanding the trends shaping and driving the global RSV market.
  • Quantify patient populations in the global RSV market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for RSV therapeutics in each of the markets
  • Understand magnitude of RSV population by prophylactic markets

Table of Contents

Table of Contents

| About GlobalData

1 Respiratory Syncytial Virus: Executive Summary

1.1 Catalyst

1.2 Related Reports

1.3 Upcoming Reports

2 Epidemiology

2.1 Disease Background

2.1.1 Risk Factors and Comorbidities

2.2 Global and Historical Trends

2.3 Forecast Methodology

2.3.1 Sources

2.3.2 Forecast Assumptions and Methods

2.4 Epidemiological Forecast for RSV Prophylactic Population (2020-2030)

2.4.1 Number of Preterm Births by Gestational Age

2.4.2 Preterm Infants with CLD

2.4.3 Number of Live Births with Hemodynamically Significant Heart Disease and Congenital Lung Disease

2.4.4 Diagnosed Prevalent Cases of DMD

2.4.5 Number of Diagnosed Prevalent Cases of SMA

2.4.6 Number of Third-Trimester Pregnant Women

2.4.7 Number of Adults Living in Nursing Homes/Long-Term Care Institutions

2.5 Discussion

2.5.1 Epidemiological Forecast Insight

2.5.2 COVID-19 Impact

2.5.3 Limitations of the Analysis

2.5.4 Strengths of the Analysis

3 Appendix

3.1 Bibliography

3.2 About the Authors

3.2.1 Epidemiologist

3.2.2 Reviewers

3.2.3 Global Director of Therapy Analysis and Epidemiology

3.2.4 Global Head and EVP of Healthcare Operations and Strategy

| Contact Us

Table

Table 1: 8MM, Summary of the Prophylactic Population in 2020

Table 2: Summary of Newly Added Data Types

Table 3: Summary of Updated Data Types

Table 4: Risk Factors for Severe RSV

Figures

Figure 1: 8MM, Rate of Preterm Births (per 1,000 Live Births), 2020-2030

Figure 2: 8MM, Percentage of Adults Living in Long-Term Care, Ages ≥55 Years, 2020-2030

Figure 3: 8MM, Sources Used to Forecast the Number of Preterm Births

Figure 4: 8MM, Sources Used to Forecast the Number of Preterm Births with CLD

Figure 5: 8MM, Sources Used to Forecast the Number of Live Births with Hemodynamically Significant Heart Disease

Figure 6: 8MM, Sources Used to Forecast the Number of Live Births with Congenital Lung Disease

Figure 7: 8MM, Sources Used to Forecast the Diagnosed Prevalent Cases of DMD

Figure 8: 8MM, Sources Used to Forecast the Diagnosed Prevalent Cases of SMA

Figure 9: 8MM, Sources Used to Forecast the Number of Third-Trimester Pregnancies

Figure 10: 8MM, Sources Used to Forecast the Number of Adults Living in Long-Term Care

Figure 11: 8MM, Number of Preterm Births by Gestational Age, N, 2020

Figure 12: 8MM, Number of Preterm Infants with CLD, N, 0-Year, 2020-2030

Figure 13: 8MM, Number of Live Births with Hemodynamically Significant Heart Disease and Congenital Lung Disease, 2020, 0-Year

Figure 14: 8MM, Diagnosed Prevalent Cases of DMD in Boys, Ages 0-2 Years, 2020-2030

Figure 15: 8MM, Diagnosed Prevalent Cases of SMA, Boys and Girls, Ages 0-2 Years, 2020-2030

Figure 16: 8MM, Number of Third-Trimester Pregnant Women, N, 2020-2030

Figure 17: 8MM, Number of Adults Living in Care Institutions, Ages ≥55 Years, N, 2020-2030

Frequently asked questions

Respiratory Syncytial Virus – Epidemiology Forecast to 2030 standard reports
Currency USD
$3,995

Can be used by individual purchaser only

$11,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Respiratory Syncytial Virus – Epidemiology Forecast to 2030 was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Respiratory Syncytial Virus – Epidemiology Forecast to 2030 in real time.

  • Access a live Respiratory Syncytial Virus – Epidemiology Forecast to 2030 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.